Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antimetabolites.
Chu E, Johnston PG, Grem JL, Takimoto CH, Van Groeningen C, Chabner BA, Allegra CJ. Chu E, et al. Among authors: van groeningen c. Cancer Chemother Biol Response Modif. 1994;15:1-31. Cancer Chemother Biol Response Modif. 1994. PMID: 7779582 Review. No abstract available.
Thymidylate synthase and drug resistance.
Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM. Peters GJ, et al. Among authors: van groeningen cj, van der wilt cl, van triest b. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299-305. doi: 10.1016/0959-8049(95)00172-f. Eur J Cancer. 1995. PMID: 7577040 Free article. Review.
Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody.
Van Triest B, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P, Telleman F, Tadema T, Aherne GW, Van Groeningen CJ, Zoetmulder FA, Taal BG, Johnston PG, Peters GJ. Van Triest B, et al. Among authors: van groeningen cj. J Histochem Cytochem. 2000 Jun;48(6):755-60. doi: 10.1177/002215540004800604. J Histochem Cytochem. 2000. PMID: 10820149
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ. Peters GJ, et al. Among authors: van gennip ah, van groeningen cj, van kuilenburg ab. Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. doi: 10.1007/s00280-003-0617-9. Epub 2003 May 9. Cancer Chemother Pharmacol. 2003. PMID: 12739060 Clinical Trial.
173 results